<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05034497</url>
  </required_header>
  <id_info>
    <org_study_id>2021-LM-001</org_study_id>
    <nct_id>NCT05034497</nct_id>
  </id_info>
  <brief_title>Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases</brief_title>
  <acronym>ReSPECT-LM</acronym>
  <official_title>A Multicenter Phase 1 Clinical Study to Determine the Maximum Tolerated Dose/Maximum Feasible Dose, Safety, and Efficacy of Single Dose Rhenium-186 NanoLiposome (186RNL) Administered Via Intraventricular Catheter for Leptomeningeal Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Plus Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Plus Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label Phase I clinical study that will administer a single dose of 186RNL via&#xD;
      intraventricular catheter for treatment of Leptomeningeal Metastases (LM).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase I clinical study evaluates a single dose of 186RNL (radionuclide clinical study&#xD;
      drug) administered through an intraventricular catheter (Ommaya reservoir) in participants&#xD;
      with Leptomeningeal Metastases (LM).&#xD;
&#xD;
      The clinical study treatment consists of a single administered 5cc dose of 186RNL per&#xD;
      participant.&#xD;
&#xD;
      The clinical study will include the evaluation of three separate dose levels. Three to six&#xD;
      participants may be treated at each dose.&#xD;
&#xD;
      The maximum number of participants to be enrolled in the study is 18.&#xD;
&#xD;
      The clinical study treatment will be administered, following a CSF flow study, on an&#xD;
      outpatient basis by the clinical study physician.&#xD;
&#xD;
      Participants will be followed for up to 12 months after the clinical study drug is&#xD;
      administered.&#xD;
&#xD;
      The U.S. Food and Drug Administration (FDA) has not approved 186RNL for this specific&#xD;
      disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 9, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events (AE) and serious adverse events (SAE)</measure>
    <time_frame>12 months</time_frame>
    <description>Safety will be evaluated by the incidence of AEs and SAEs graded according CTCAE version 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities (DLT)</measure>
    <time_frame>12 months</time_frame>
    <description>Maximum Tolerated Dose (MTD) will be evaluated by testing increasing doses for cohorts 1 to 3 with 3 to 6 participants in each cohort. MTD reflects the highest dose of drug that did not cause a Dose-Limiting Toxicity (DLT) in &gt; 33% of participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of the overall response rate (ORR)</measure>
    <time_frame>12 months</time_frame>
    <description>Determine the overall response rate (ORR) defined as the proportion of all evaluable participants achieving a response as the best overall response at the time of progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of the duration of response (DoR)</measure>
    <time_frame>12 months</time_frame>
    <description>Determine the duration of response (DoR) defined as the time from first response to LM progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of progression free survival (PFS)</measure>
    <time_frame>12 months</time_frame>
    <description>Determine progression free survival (PFS) defined as the time from first treatment to date of LM progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>12 Months</time_frame>
    <description>Determine the overall survival (OS) define as the time from first treatment to date of death.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Leptomeningeal Metastasis</condition>
  <arm_group>
    <arm_group_label>Dose Escalation for Cohorts 1-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant will receive a single 5cc administration of 186RNL.&#xD;
At each dose level, a minimum of three to a maximum of six participants will be enrolled.&#xD;
If no dose limiting toxicity is observed in the initial three participants, then the next higher dose level cohort will open for enrollment.&#xD;
The dose escalation scheme will follow a modified Fibonacci dose escalation scheme as shown below:&#xD;
COHORT ACTIVITY Cohort 1 (6.6 mCi) Cohort 2 (13.2 mCi) Cohort 3 (26.4 mCi)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>186RNL</intervention_name>
    <description>All participants will be required to have an Ommaya Reservoir and a CSF Flow Study.&#xD;
Participants will receive a single 5cc dose of 186RNL via Ommaya Reservoir.</description>
    <arm_group_label>Dose Escalation for Cohorts 1-3</arm_group_label>
    <other_name>Rhenium-186 NanoLiposome</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. At least 18 years of age at time of screening.&#xD;
&#xD;
          2. Ability to understand the purposes and risks of the study and has signed a written&#xD;
             informed consent document approved by the site-specific IRB.&#xD;
&#xD;
          3. Subject has proven and documented LM that meets the requirements for the study:&#xD;
&#xD;
             • EANO-ESMO Clinical Practice Guidelines Type 1 and 2 (with the exception of 2D) LM of&#xD;
             any primary type.&#xD;
&#xD;
          4. Karnofsky performance status of 60 to 100&#xD;
&#xD;
          5. Acceptable liver function:&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 times upper limit of normal&#xD;
&#xD;
               -  AST (SGOT) and ALT (SGPT) ≤ 5.0 times upper limit of normal&#xD;
&#xD;
               -  Acceptable renal function with serum creatinine ≤ 2 times upper limit of normal&#xD;
&#xD;
          6. Acceptable hematologic status (without hematologic support):&#xD;
&#xD;
               -  ANC ≥1000 cells µL&#xD;
&#xD;
               -  Platelet count ≥75,000/µL&#xD;
&#xD;
               -  Hemoglobin ≥9.0 g/dL&#xD;
&#xD;
          7. All women of childbearing potential must have a negative serum pregnancy test at&#xD;
             screening. Male and female subjects must agree to use effective means of contraception&#xD;
             (for example, surgical sterilization or the use of barrier contraception with either a&#xD;
             condom or diaphragm in conjunction with spermicidal gel or an IUD) with their partner&#xD;
             from entry into the study through 6 months after the last dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The subject has not recovered to National Cancer Institute (NCI) Common Terminology&#xD;
             Criteria for Adverse Events (CTCAE v5.0 Grade ≤ 1 from AEs (except alopecia, anemia&#xD;
             and lymphopenia) due to antineoplastic agents, investigational drugs, or other&#xD;
             medications that were administered prior to study.&#xD;
&#xD;
          2. Obstructive or symptomatic communicating hydrocephalus&#xD;
&#xD;
          3. Ventriculo-peritoneal or ventriculo-atrial shunts without programable valves or&#xD;
             contraindications to placement of Ommaya reservoir&#xD;
&#xD;
          4. Females of childbearing potential who are pregnant, breast feeding, or may possibly be&#xD;
             pregnant without a negative serum pregnancy test&#xD;
&#xD;
          5. Serious intercurrent illness, such as progressive systemic (extra leptomeningeal)&#xD;
             disease, clinically significant cardiac arrhythmias, uncontrolled systemic infection,&#xD;
             symptomatic congestive heart failure or unstable angina pectoris within 3 months prior&#xD;
             study drug, myocardial infarction, stroke, transient ischemic attack within 6 months,&#xD;
             seizure disorder with any seizure occurring within 14 days prior to consenting or&#xD;
             encephalopathy&#xD;
&#xD;
          6. Active severe non hematologic organ toxicity such as renal, cardiac, hepatic,&#xD;
             pulmonary, or gastrointestinal systemic toxicity grade 3 or above.&#xD;
&#xD;
          7. Significant coagulation abnormalities such as inherited bleeding diathesis or acquired&#xD;
             coagulopathy with unacceptable risks of bleeding.&#xD;
&#xD;
          8. Craniospinal irradiation (for intraparenchymal or dural metastasis) or intrathecal&#xD;
             cytotoxic anti-cancer therapy less than 3 weeks prior to first dose of 186RNL.&#xD;
&#xD;
          9. Myelopathy following spinal irradiation greater than 3 weeks prior to the first dose&#xD;
             of 186RNL.&#xD;
&#xD;
         10. Systemic chemotherapeutic agents with CNS penetration (such as temozolomide,&#xD;
             carmustine, lomustine, capecitabine, carboplatin, vinorelbine, bevacizumab, irinotecan&#xD;
             or topotecan) unless they develop or have progressive or persistent leptomeningeal&#xD;
             metastases while on these agents.&#xD;
&#xD;
         11. Systemic therapy (including investigational agents and small-molecule kinase&#xD;
             inhibitors) within 14 days or 5 half-lives, whichever is shorter, prior first dose of&#xD;
             study drug (186RNL).&#xD;
&#xD;
         12. Nitrosoureas or mitomycin C within 42 days, or metronomic/protracted low-dose&#xD;
             chemotherapy within 14 days, or other cytotoxic chemotherapy within 28 days, prior to&#xD;
             first dose of study drug (186RNL).&#xD;
&#xD;
         13. Impaired CSF Flow Study performed on Day -4 to Day -2 based on study imaging and as&#xD;
             determined by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Hedrick, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Plus Therapeutics, President and CEO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Sereno</last_name>
    <phone>1-512-658-7591</phone>
    <email>lsereno@plustherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erika Butler, MS</last_name>
    <phone>1-210-787-7972</phone>
    <email>ebutler@plustherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UT Health Science Center San Antonio / Mays Cancer Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Epp Goodwin</last_name>
      <phone>210-450-5798</phone>
    </contact>
    <contact_backup>
      <last_name>Maggie Tomasini</last_name>
      <phone>210-450-5961</phone>
    </contact_backup>
    <investigator>
      <last_name>Andrew J Brenner, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>William T Phillips, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Floyd, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Meningeal Carcinomatosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

